Why Gain Therapeutics, Inc.’s (GANX) Stock Is Down 6.74%
As of Wednesday, October 14, Gain Therapeutics, Inc.’s GANX share price has dipped by 6.74%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Michael Rose
Jenna Brashear
Cynthia McLaughlin
Michael Rose
| Share Statistics | GANX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $44.5 | $203.5 | 17% |
|
| Shares Out (Mil) | 43.8 | 55.2 | 44% |
|
| Institutional Ownership | 89.6% | 93.3% | 57% |
|
| Float (Mil) | 43.5 | 40.4 | 43% |
|
| Beta | 0.30 | 1.05 | 17% |
|
| Avg Daily Volume (000s) | 881 | 569 | 68% |
|
| Price Change (52-week) |
(63.7%) | 38.8% | 16% |
|
| Growth | GANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (41.2%) | (10.7%) | 9% |
|
| EPS (5yr) | 14.4% | 15.4% | 55 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (34.6%) | (15.7%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.083) | ($0.393) | ($0.600) | |
| Month Ago EPS | ($0.135) | ($0.505) | ($0.688) | |
| # Rev Up | 3 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.127) | ($0.503) | ($0.543) | |
| Year/Year Chg | 15.3% | (35.8%) | 37.3% | |
| Financials | GANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($44) | 24% |
|
| EPS (TTM) | ($0.431) | ($1.400) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($35) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 14% |
|
| Enterprise Value (Q1) (Mil) | $41 | $142 | 16% |
|
| Valuation | GANX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.35 | 1.96 | 80% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GANX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (148.6%) | (47.0%) | 3% |
|
| ROE | (223.9%) | (51.8%) | 3% |
|
| Liabilities to Assets | 23.3% | 29.6% | 15% |
|
| F-Score | 3 | 3 | 18% |
|
Gain Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors